News & Publications › Latest News  

Latest News

April 29, 2021

Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders

April 26, 2021

Matthew During, M.D., Ph.D. to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics

April 19, 2021
Brooklyn ImmunoTherapeutics Reports Inducement Grants

April 16, 2021
Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders

April 15, 2021
Dennis H. Langer, M.D., J.D. to Join the Board of Directors of Brooklyn ImmunoTherapeutics, Inc.

April 6, 2021
Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc.

March 25, 2021
Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime

February 09, 2021
Brooklyn ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Triple Negative Breast Cancer

August 13, 2020
NTN Buzztime, Inc. and Brooklyn ImmunoTherapeutics LLC Enter into Definitive Merger Agreement

March 2, 2020
2020 Head and Neck Cancers Symposium: Immune Restorative Agent May Boost Immunotherapy Response in Advanced Head and Neck Cancer

June 3, 2019
Brooklyn ImmunoTherapeutics Announces Presentation of Ongoing Investigator Sponsored Trial of IRX-2 Regimen Combined with Nivolumab in Recurrent/Metastatic Solid Tumors

April 8, 2019
New clinical trials to investigate combination immunotherapy for treating advanced cancers

November 10, 2018
Brooklyn ImmunoTherapeutics Announces Presentation of Positive Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer

November 7, 2018
Brooklyn ImmunoTherapeutics Acquires IRX Therapeutics

November 7, 2018
Brooklyn ImmunoTherapeutics Announces Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer Accepted for Oral Presentation at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer